AR128234A1 - Inhibidores de la ras - Google Patents
Inhibidores de la rasInfo
- Publication number
- AR128234A1 AR128234A1 ARP230100052A ARP230100052A AR128234A1 AR 128234 A1 AR128234 A1 AR 128234A1 AR P230100052 A ARP230100052 A AR P230100052A AR P230100052 A ARP230100052 A AR P230100052A AR 128234 A1 AR128234 A1 AR 128234A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- membered
- pharmaceutically acceptable
- compound
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263298098P | 2022-01-10 | 2022-01-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128234A1 true AR128234A1 (es) | 2024-04-10 |
Family
ID=85199574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100052A AR128234A1 (es) | 2022-01-10 | 2023-01-09 | Inhibidores de la ras |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250197423A1 (https=) |
| EP (1) | EP4463231A1 (https=) |
| JP (1) | JP2025503641A (https=) |
| KR (1) | KR20240132492A (https=) |
| CN (2) | CN118922423A (https=) |
| AR (1) | AR128234A1 (https=) |
| AU (1) | AU2023204824A1 (https=) |
| CA (1) | CA3246887A1 (https=) |
| CL (2) | CL2024002041A1 (https=) |
| CO (1) | CO2024010814A2 (https=) |
| CR (1) | CR20240276A (https=) |
| IL (1) | IL314033A (https=) |
| MX (1) | MX2024008561A (https=) |
| PE (1) | PE20241892A1 (https=) |
| TW (1) | TW202330553A (https=) |
| WO (1) | WO2023133543A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| WO2023240263A1 (en) * | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN119546613A (zh) * | 2022-07-08 | 2025-02-28 | 豪夫迈·罗氏有限公司 | 可用作kras抑制剂的大环化合物 |
| CN119522225A (zh) | 2022-09-29 | 2025-02-25 | 广州嘉越医药科技有限公司 | 大环衍生物及其应用 |
| WO2024104364A1 (zh) * | 2022-11-16 | 2024-05-23 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| CR20250329A (es) | 2023-02-14 | 2025-09-12 | Hoffmann La Roche | Compuestos tricíclicos para el tratamiento del cáncer |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025104149A1 (en) * | 2023-11-16 | 2025-05-22 | F. Hoffmann-La Roche Ag | Macrocyclic compounds as kras mutant inhibitors for the treatment of cancer |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025213065A1 (en) * | 2024-04-05 | 2025-10-09 | Revolution Medicines, Inc. | Peptide conjugates |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| CN120699039A (zh) * | 2019-11-04 | 2025-09-26 | 锐新医药公司 | Ras抑制剂 |
| WO2021091956A1 (en) * | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202304452A (zh) * | 2021-04-09 | 2023-02-01 | 美商銳新醫藥公司 | Ｓｏｓ１抑制劑與ｒａｓ抑制劑於治療癌症之用途 |
| CA3217393A1 (en) * | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| MX2023013912A (es) * | 2021-05-25 | 2024-02-12 | Revolution Medicines Inc | Metodos para inhibir ras. |
-
2023
- 2023-01-09 CN CN202380026429.5A patent/CN118922423A/zh active Pending
- 2023-01-09 CR CR20240276A patent/CR20240276A/es unknown
- 2023-01-09 MX MX2024008561A patent/MX2024008561A/es unknown
- 2023-01-09 AU AU2023204824A patent/AU2023204824A1/en active Pending
- 2023-01-09 CA CA3246887A patent/CA3246887A1/en active Pending
- 2023-01-09 KR KR1020247026507A patent/KR20240132492A/ko active Pending
- 2023-01-09 IL IL314033A patent/IL314033A/en unknown
- 2023-01-09 AR ARP230100052A patent/AR128234A1/es unknown
- 2023-01-09 EP EP23704026.6A patent/EP4463231A1/en active Pending
- 2023-01-09 TW TW112100804A patent/TW202330553A/zh unknown
- 2023-01-09 JP JP2024541159A patent/JP2025503641A/ja active Pending
- 2023-01-09 WO PCT/US2023/060288 patent/WO2023133543A1/en not_active Ceased
- 2023-01-09 PE PE2024001555A patent/PE20241892A1/es unknown
- 2023-01-09 CN CN202411889987.7A patent/CN119798279A/zh active Pending
-
2024
- 2024-07-04 CL CL2024002041A patent/CL2024002041A1/es unknown
- 2024-07-10 US US18/769,009 patent/US20250197423A1/en active Pending
- 2024-08-08 CO CONC2024/0010814A patent/CO2024010814A2/es unknown
-
2025
- 2025-03-28 CL CL2025000954A patent/CL2025000954A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL314033A (en) | 2024-09-01 |
| MX2024008561A (es) | 2024-07-22 |
| CO2024010814A2 (es) | 2024-08-20 |
| CL2024002041A1 (es) | 2024-12-20 |
| CN118922423A (zh) | 2024-11-08 |
| CR20240276A (es) | 2024-08-23 |
| JP2025503641A (ja) | 2025-02-04 |
| US20250197423A1 (en) | 2025-06-19 |
| EP4463231A1 (en) | 2024-11-20 |
| WO2023133543A1 (en) | 2023-07-13 |
| PE20241892A1 (es) | 2024-09-19 |
| CA3246887A1 (en) | 2023-07-13 |
| AU2023204824A1 (en) | 2024-07-18 |
| CN119798279A (zh) | 2025-04-11 |
| TW202330553A (zh) | 2023-08-01 |
| CL2025000954A1 (es) | 2025-08-01 |
| KR20240132492A (ko) | 2024-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR128234A1 (es) | Inhibidores de la ras | |
| AR127308A1 (es) | Inhibidores ras | |
| AR125782A1 (es) | Inhibidores de ras | |
| AR125787A1 (es) | Inhibidores de ras | |
| CL2021003202A1 (es) | Compuestos de pirrolidina | |
| ECSP22012347A (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr | |
| AR102722A2 (es) | Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit | |
| ES2018112A6 (es) | Un procedimiento de preparacion de derivados de 4h-1-benzopiran-4-ona o sus sales. | |
| AR114679A1 (es) | Compuestos heterocíclicos fungicidas | |
| AR118613A1 (es) | Compuestos de oxadiazol para controlar o prevenir hongos fitopatogénicos | |
| CO2022003123A2 (es) | Compuestos farmacéuticos | |
| AR121744A1 (es) | MODULADORES DE a 1-ANTITRIPSINA | |
| AR129339A1 (es) | Inhibidores de parg | |
| SE7612053L (sv) | Forfarande for framstellning av enolderivat | |
| CO2021014210A2 (es) | Compuestos de pirrol | |
| AR127483A1 (es) | Compuestos antibacterianos | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| AR080228A1 (es) | Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacion | |
| DOP2025000090A (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| CL2023002722A1 (es) | Derivados de morfolinas sustituidas y usos de estos | |
| CO2025013218A2 (es) | Derivados de morfolinas sustituidas y usos de estas | |
| AR029001A1 (es) | Derivados de bencil-3,4-metilendioxicinamico y el uso de los mismos para la manufactura de un medicamento | |
| AR042687A1 (es) | Pirimidinas sustituidas y su uso como inhibidores de mmp-13 selectivos. procedimiento de preparacion y composiciones farmaceuticas. | |
| CL2024002500A1 (es) | Inhibidores de proteínas de unión a emopamilo y usos de estos | |
| AR127185A1 (es) | Compuestos de pirazolopiridina como inhibidores de tam |